Status: Not yet recruiting
VEL-101 to Prevent Rejection After Kidney Transplantation
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Veloxis PharmaceuticalsUpdated: Dec 18, 2025
Eligibility criteria
Greater than or equal to 18 years of age [+7]
Negative for EBV or Epstein-Barr nuclear antigen antibody [+23]